The Washington Post reveals that a shocking secret investigative report by a Nigerian government panel of medical experts concluded that Pfizer Pharmaceuticals conducted an unethical drug experiment in Nigeria in 1996.
Under the influence of pharmaceutical companies, physicians anhd drug companies engage in "disease mongering." Below is a critique of Dr. David Healy’s essay: Dr. Nassir Ghaemi who argues for the legitimacy of bipolar diagnosis.
"Corruption in any one of the critical decision points in the pharmaceutical system can be detrimental to a country’s ability to improve the health of its population." [World Banki]
Three reports illustrate the wide and deepening disconnect between medicine under the influence of pharmaceutical industry marketing goals and scientific evidence that contradicts current practice and public health policies:
Dr. Robert Spitzer, who has continued to play a central role in DSM revisions since 1980, claim he does not think a conflict of interest exists.
See list of APA Task Force on DSM-IV and DSM-IV Revised Text at: https://ahrp.org/cms/content/view/145/27/
"Are we becoming patients for profit? That is the question knowledgeable observers are asking.
The Pharmaceutical industry rakes in $500 billion globally–$230 billion in North America–57% of revenues is on marketing.
Newly published results (phase II) from the CATIE schizophrenia treatment efficacy study sponsored by the National Institute of Mental Health comparing the most commonly used second generation drug treatments for schizophrenia and depression, is highly disturbing.
The Center for Public Integrity reports that FDA officials circumvent the prohibition on accepting trips from drug and medical device manufacturers.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
Unless Congress acts to overrule the FDA, research disasters such as occurred in London, when six healthy men were exposed to an experimental substance that brought them close to death, are likely to occur with increased frequency.
Below a press release from the lawfirm, Baum Hedlund, announces it has filed a class action lawsuit against GlaxoSmithKline charging the company with fraud, negligence, strict liability, and breach of warranty in its marketing of Paxil (Seroxat) by concealing the risk of suicide.
